Tcelna
Tcelna
Tcelna (pronounced: te-sel-na) is a type of immunotherapy that was developed for the treatment of Multiple Sclerosis (MS). It is a personalized T-cell therapy that is designed to reduce the immune system's attack on the myelin sheath, a protective covering for nerve fibers in the central nervous system.
Etymology
The term 'Tcelna' is a brand name and does not have a known etymology. It is a proprietary name given by the pharmaceutical company Opexa Therapeutics, which developed the therapy.
Description
Tcelna is a type of autologous T-cell immunotherapy. This means that it uses the patient's own T-cells, which are a type of white blood cell that plays a key role in the immune system. In the case of Tcelna, the T-cells are extracted from the patient's blood, modified in a laboratory to make them less aggressive, and then re-injected into the patient. The aim is to reduce the immune system's attack on the myelin sheath, which is a common feature of MS.
Related Terms
- Immunotherapy: A type of treatment that uses the body's own immune system to fight disease.
- Multiple Sclerosis: A chronic disease that affects the central nervous system, causing a range of symptoms that can include fatigue, difficulty walking, numbness or tingling, muscle weakness, and problems with coordination and balance.
- Opexa Therapeutics: A pharmaceutical company that specializes in the development of personalized immunotherapies for autoimmune disorders, such as MS.
- Autologous: Referring to cells, tissues, or even proteins that are re-infused back into the same individual from which they came.
External links
- Medical encyclopedia article on Tcelna
- Wikipedia's article - Tcelna
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski